Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ANG 1005 in patients with HER- and HER+ breast cancer and brain metastases

Trial Profile

ANG 1005 in patients with HER- and HER+ breast cancer and brain metastases

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel trevatide (Primary)
  • Indications Advanced breast cancer; Brain metastases
  • Focus Therapeutic Use
  • Sponsors Geron Corporation
  • Most Recent Events

    • 21 Nov 2013 New trial record
    • 23 Oct 2013 Results from the complete intention-to-treat population, including prematurely withdrawn patients, presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
    • 22 Oct 2013 Data Presented at 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top